Search results for "ion therapy"

showing 10 items of 1072 documents

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

Guillain-Barré syndrome after orthotopic liver transplantation: A clinical manifestation of immune reconstitution inflammatory syndrome?

2018

Guillain-Barrè Syndrome, as part of the spectrum of dysimmune neuropathies, is unexpected to occur in immunocompromised hosts. We describe a clinical case of Guillain-Barrè syndrome, occurred a few weeks after a liver transplant, and we postulate that our case would satisfy all requirements to explain this peripheral nervous system complication as a clinical manifestation of an Immune reconstitution inflammatory syndrome. In this setting of liver transplantation, complicated by potentially multiple infective triggers, reduction of immunosuppression and reversal of pathogen-induced immunosuppression, through antimicrobial therapy, may have led to pro-inflammatory response. The pro-inflammato…

medicine.medical_treatmentLiver transplantationGuillain-Barre SyndromeTacrolimus030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineImmune systemImmune reconstitution inflammatory syndromemedicineHumansImmune reconstitution inflammatory syndromeAcute demyelinating polyneuropathyImmunosuppression TherapyInflammationLiver transplantationGuillain-Barre syndromebusiness.industryImmunosuppressionGeneral Medicinemedicine.diseaseGuillain-Barré syndromeTacrolimusPathophysiologyTacrolimuImmunologyAcute demyelinating polyneuropathy; Guillain-Barré syndrome; Immune reconstitution inflammatory syndrome; Liver transplantation; TacrolimusSurgeryFemaleNeurology (clinical)Complicationbusiness030217 neurology & neurosurgery
researchProduct

Role of muscle-targeted nutritional therapy: new data.

2022

Purpose of review To provide an updated overview of recent efficacy data on the use of muscle-targeted nutritional therapy, which should consider the optimization of protein and essential amino acids intakes, possibly in combination with supplementation with vitamin D (correction of deficiency/insufficiency status) and v-3 fatty acids. Recent findings Intervention studies conducted in the last years in different healthcare settings and heterogeneous patient populations support the use of muscle-targeted oral nutritional supplementation to improve muscle mass, function and physical performance in patients with sarcopenia. Higher efficacy is likely to be achieved in combination with individua…

muscle mass muscle strength nutritional therapy physical performance sarcopeniaSarcopeniaNutrition and DieteticsMuscular DiseasesDietary SupplementsMedicine (miscellaneous)HumansMuscle StrengthNutrition TherapyVitamin DMuscle SkeletalCurrent opinion in clinical nutrition and metabolic care
researchProduct

Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease.

2010

The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue for the gastroenterologist. Until to 10 years ago, immunosuppressors, mainly azathioprine or 6-mercaptopurine, were the best possible treatments available, and remission rates ranged from 30 to 60% according to the results of open studies and controlled trials. Recently, infliximab has been shown to be effective in steroid-dependent patients and, combined with azathioprine, it has been shown to increase 1-year remission rates. A recent large randomized controlled trial comparing infliximab, azathioprine and infliximab plus azathioprine demonstrated that the combination of infliximab plus azath…

musculoskeletal diseasesCrohn's diseasemedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologyCombination therapybusiness.industryGastroenterologyAzathioprinemedicine.diseaseGastroenterologyInfliximablaw.inventionSurgeryRandomized controlled triallawInternal medicinemedicineInfliximab azathioprine Crohnbusinessmedicine.drug
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Glucocorticoid-sensitive hereditary inclusion body myositis.

1996

We report a hereditary muscle disorder with features of inclusion body myositis (IBM) in two adult sisters with slowly progressive asymmetrical muscle weakness. The findings of light microscopic and ultrastructural investigations of muscle biopsy specimens were consistent with a diagnosis of IBM. Both patients improved and stabilized on immunosuppressive treatment with corticosteroids and azathioprine. This differentiates our patients from other sporadic and familial cases of IBM. Clinical and histological features are described and compared with those of other previously reported families with IBM.

musculoskeletal diseasesPathologymedicine.medical_specialtyNeurologyeducationMuscle Fibers SkeletalAzathioprineMuscle disorderMyositis Inclusion Bodyparasitic diseasesmedicineHumansGlucocorticoidsMyositisImmunosuppression TherapyMuscle biopsymedicine.diagnostic_testbusiness.industryMuscle weaknessMiddle Agedmedicine.diseasePrognosisMicroscopy ElectronNeurologyFemaleNeurology (clinical)medicine.symptomInclusion body myositisbusinessGlucocorticoidmedicine.drugJournal of neurology
researchProduct

Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy

2019

Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has investigated determinants of bone strength beyond DXA-derived areal bone mineral density (aBMD) in this population group. The aim of this cross-sectional study was to investigate the effects of ADT in men with PCa on BMD, bone structure, estimates of whole bone strength and cortical bone distribution. A total of 70 ADT-treated men, 52 PCa controls and 70 healthy controls had DXA lumbar spine and proximal femur aBMD and pQCT distal (4%) and proximal (66%) tibia and radius c…

musculoskeletal diseasesbone distributionsyöpähoidoteturauhassyöpähormonihoitoluuntiheysandrogen deprivation therapybone strengthbone mineral densityluukudokset
researchProduct

Juxtacortical mandibular chondrosarcoma during pregnancy : a case report

2017

Chondrosarcoma is one of the most common malignant bone tumors in adults. It use to affect upper arm, pelvis and thigh bone. A wide surgical extirpation represent the gold standard to treat this disorder. In fact, radiotherapy and chemotherapy are no useful. Interestingly, chondrosarcoma is rare in head and neck (HNCS) and extremely uncommon during pregnancy. Thus, there is a lack of evidence about the proper treatment in these cases. A wide surgical extirpation is also considered the most effective procedure in HNCS. There are no consistent evidences about the he role of radiation and chemotherapy. In view of that, the present study describes a case of juxtacortical mandibular chondrosarco…

musculoskeletal diseasesmedicine.medical_specialtymedicine.medical_treatmentCase ReportThigh03 medical and health sciences0302 clinical medicineMedicineGeneral DentistryPelvisChemotherapyPregnancyOral Medicine and Pathologybusiness.industryMultidisciplinary analysisGold standard030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryRadiation therapymedicine.anatomical_structure030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASChondrosarcomabusiness
researchProduct

Endothelial Function in Obese Patients Treated with Bariatric Surgery

2020

Antonio Maria Borzì,1,2,* Carola Buscemi,3,4,* Davide Corleo,3,4 Cristiana Randazzo,3,4 Giuseppe Rosafio,3,4 Gianni Pantuso,5 Silvio Buscemi3,4 1Department of Clinical and Experimental Medicine, Specialization School in Geriatrics, University of Catania, Catania, Italy; 2Specialization School in Geriatrics, Catania, Italy; 3Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, Palerno, Italy; 4Unit of Malattie Endocrine, del Ricambio e della Nutrizione, Policlinico University Hospital, Palermo, Italy; 5Dipartimento di Discipline Chirurgiche e Odontostomatologiche (DICHIRONS), Unit of Chirurgia Onco…

obesityendothelial functionRC581-951bariatric surgerySpecialties of internal medicineSettore MED/49 - Scienze Tecniche Dietetiche Applicatemedical nutrition therapyDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct